cLICK Here for poster submission

CALL FOR ABSTRACTS

 

This is the first call for abstracts and announcement of the 2nd INTERNATIONAL SYMPOSIUM IN NEUROSCIENCE (December, 17-19th, 2018), which will be held at Sonata Hotel in Fortaleza, Ceara, along with instructions for submitting abstracts. We are looking forward to having the abstracts submitted as soon as possible for our three-day meeting. The scientific program board has decided to define a deadline of December, 07th, which will allow us to distribute the abstract book on line in a timely manner. Please review the instructions for submitting abstracts. We are trying to make this as easy as possible. Abstracts from all speakers are strongly encouraged so that we have a good representation of the meeting lectures. An abstract book will appear in the meeting website (www.ibisab.ufc.br/sine2018). Thank you!

 

To:     All invited speakers and attendees of the II INTERNATIONAL SYMPOSIUM IN NEUROSCIENCE

 

Dt:     December, 17-19th, 2018

 

 

CALL FOR ABSTRACTS

 

The II INTERNATIONAL SYMPOSIUM IN NEUROSCIENCE (ISN) will be held on December, 17th (Monday) to December 19th (Wednesday) in Fortaleza, CE, Brazil. All researchers and students from the Institute of Biomedicine of the Brazilian Semiarid (INCT-IBISAB, www.ibisab.ufc.br) and CAPES/Print related-laboratories from the Federal University of Ceara and other neighbor Universities are welcome to attend the meeting. Abstracts selected for the meeting will be gathered into two daily sessions, taking into account related topics. In due time, we encourage all participants to confirm the attendance interest.  PIs, fellows, students, and others in training who have participated in clinical or basic research during the last 12 months are encouraged to submit abstracts. Due to time constraint, all poster presentations will have 10 min in a digital screen. Therefore, we should have digital presentations only (not printed posters). Digital posters should be 38,1 cm (width) X 65,969 cm (height).

 

All invited speakers and attendees are encouraged to submit an abstract regarding his/her talk. Abstract instructions are given below. If you have any questions or need additional information, please contact Reinaldo B. Oria by sending an e-mail to simposioneurocienciasufc2018@gmail.com.

 

ABSTRACT DEADLINE:  DECEMBER 7th, 2018

PLEASE MARK YOUR CALENDARS!

II International Symposium in Neuroscience Meeting

December, 17-19th, Fortaleza-CE/Brazil

 

(Instructions)

 

Abstracts (limited to a single page) should focus on representing the invited talk o ongoing research. Abstracts submitted for presentation at other scientific meetings within the last year are acceptable, but should be updated to reflect the current status of your research. Note that the abstract should reflect the oral presentations to be given at the I International Symposium in Neuroscience Meeting, Fortaleza-CE, 2013.

Please acknowledge the sources of funding for your research beneath your abstract, especially funding from NIH or Brazilian CNPq/CAPES grants. Submit your abstract via e-mail to Reinaldo Barreto Oria (e-mail: simposioneurocienciasufc2018@gmail.com).Receipt of your abstract will be confirmed by return e-mail. If you haven’t received confirmation within 48 hours, or if you need more information, please contact Reinaldo Oria by the following e-mail address: oria@ufc.br. Note that the email address

simposioneurocienciasufc2018@gmail.com is the only recipient address to submit abstracts.

ABSTRACT DEADLINE:  December 07th, 2018 (UPDATED!)

 

Additional Format Guidelines:

 

• Abstracts should be sent via e-mail in a Word application.
• Margins (top, bottom, left and right) should be one inch.
• Please make sure your Abstracts are in 12 pt. ARIAL font.
• Each Abstract should have a bolded title, followed by the author(s), and their department and division names.

 

Each Abstract should be structured by

1. Background,
2. Objective,
3. Design/ Methods,
4. Results, and
5. Conclusions.

 

• The Abstract is limited to one page.

• Acknowledge funding, especially grants awarded by NIH and Brazilian CNPq grants, beneath your Abstract.

 

Thank you for submitting your abstract. We are looking forward to including your work in the I International Symposium in Neuroscience Meeting. See sample Abstract below:

 

*Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy

 

Juan Maciasa, José C. Palomaresb, José A. Miraa, María J. Torresc, José A. García-Garcíaa, José M. Rodríquezc, Salvador Vergeraa and Juan A. Pinedad,

 

aServicio de Medicina Interna, Hospital Universitario de Valme, Seville, Spain

bServicio de Microbiología, Hospital Universitario de Valme, Seville, Spain

cServicio de Microbiología, Hospital Universitario Virgen Macarena, Seville, Spain

dUnidad Clínica de Enfermedades Infecciosas, Hospital Universitario de Valme, Seville, Spain

 

Background: There are very few and contradictory data about the consequences of ‘blips’, transient rebounds of HIV viremia. We assessed the emergence of new drug resistance mutations during blips among HIV-infected patients on HAART from a cohort in which we found no association between blips and virological failure.

 

Design/Methods: Seventeen patients with blips were selected from 330 patients under HAART for over 48 weeks according to these criteria: (1) presence of only one blip, viremia ≤1000 copies/ml preceded by two consecutive visits and followed by one visit showing undetectable viremia; (2) therapy adherence ≥95%; (3) availability of frozen sera.

 

Results: HIV RNA could be extracted and amplified from five patients. In another two patients only the protease region could be amplified. Drug mutations in either the retrotranscriptase or protease genes, not detected at baseline, were observed in six patients at the blip. None of the patients showed detectable viremia during a median (range) follow-up after the blip of 120 (36–156) weeks.

 

Conclusions: Transient rebounds of viremia in patients on HAART are associated with the emergence of new drug resistant HIV variants. In spite of it, virological failure is not observed after a median follow-up of over 2 years.

 

Funded by the Grant-In-Aid and NIH T32H207956.

* the abstract shown above is used for template purpose only.